Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Monday, May 27, 2024 for the Memorial Day holiday. Have a healthy, happy holiday.

Hide

Paraneoplastic neurological syndromes

Early detection and quick treatment can make a difference

Paraneoplastic neurological syndromes (PNS) are a group of disorders that develop in some people who have cancer. In 60% of patients with PNS, the symptoms occur before the diagnosis of cancer is made.1

Enhanced detection of neuronal cell-surface antigens can accelerate diagnosis and treatment

The Paraneoplastic Antibody Expanded Evaluation from Quest can identify 25 prevalent antibodies, including Ma2/Ta and Zic4. Utilizing CBA methodology as part of the initial panel instead of a reflex increases the likelihood of identifying membrane-embedded protein targets, NMDA (NR1), LGI1, CASPR2, AMPAR, and GABABR.

The Paraneoplastic Antibody Expanded Evaluation from Quest always uses a cell-based assay (CBA) as part of the initial panel assessment 

 

Detection of central nervous system autoantibodies is generally better achieved with CBAs2

 

Utilizing CBA increases the likelihood of identifying membrane-embedded protein targets, LGI1, CASPR2, NMDA (NR1), AMPAR, and GABABR

   3 important reasons to test for PNS
  1. Identify PNS antibodies that can increase the likelihood of early diagnosis and treatment
  2. Understand disease progression and prognosis so you and your patients know what to expect
  3. Discover comorbidities or underlying conditions such as encephalitis, ataxia, or myasthenia gravis so you can plan the right care pathway

By screening patients for multiple autoantibodies, the detection rate for diagnostically relevant autoantibodies increased by 87%, compared to single testing of requested analytes 3

Why order PNS testing from Quest

References

1. National Organization for Rare Disorders. Paraneoplastic neurologic syndromes. Updated 2016. Accessed October 20, 2021. https://rarediseases.org/rare-diseases/paraneoplasticneurologic-syndromes/

2. Abelhosn RW, Montana L, Rivera JG, et al. Tissue immunofluorescence confirmation of CNS autoantibodies identified by immunoblot or cell-based assay. J Neurosci Neuropsych. 2021;103:4. Online ahead of print, December 15, 2020. http://article.scholarena.com/Tissue-Immunofluorescence-Confirmation-of-CNS.pdf

3. Stocker W, Probst C, Teegen B, et al. Multiparameter autoantibody screening in the diagnosis of neurological autoimmune diseases. Paper presented at: 2nd International Conference on Antibodies and Therapeutics; July 11-12, 2016; Philadelphia, PA. Immunome Res. 2016;12 (2)(Suppl). https://www.longdom.org/

Join our email community 

Get the very latest news and information from Quest Advanced® Neurology.

Sign up